OvaScience Inc (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced that physicians continue to report improvements in pregnancy rates and live births with the AUGMENTSM treatment in women with very poor prognoses, including those with poor egg health and embryo quality. At a scientific symposium held during the European Society for Human Reproduction and Embryology (ESHRE) annual meeting, fertility experts discussed the importance of egg health for improving patient care and shared their patients’ experiences using the AUGMENT treatment during in vitro fertilization (IVF). The AUGMENT treatment is not available in the United States.

Speaking from the conference, Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience, said, “We were pleased to host fertility specialists from more than forty countries at our scientific session, which focused on improving egg health and featured additional positive patient experiences with the AUGMENT treatment. The clinical pregnancy rates and live births reported by physicians using the AUGMENT treatment are encouraging, and we look forward to more patients having access to the treatment.” (Original Source)

Shares of OvaScience Inc closed yesterday at $38.74 . OVAS has a 1-year high of $55.69 and a 1-year low of $8.15. The stock’s 50-day moving average is $31.19 and its 200-day moving average is $38.29.

On the ratings front, OvaScience Inc has been the subject of a number of recent research reports. In a report issued on June 2, Wedbush analyst Zarak Khurshid reiterated a Buy rating on OVAS, with a price target of $52, which implies an upside of 34.2% from current levels. Separately, on May 18, Oppenheimer’s Rohit Vanjani reiterated a Buy rating on the stock and has a price target of $60.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Zarak Khurshid and Rohit Vanjani have a total average return of 6.1% and 41.4% respectively. Khurshid has a success rate of 68.2% and is ranked #1109 out of 3629 analysts, while Vanjani has a success rate of 83.3% and is ranked #10.

In total, 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $70.50 which is 82.0% above where the stock closed yesterday.

OvaScience Inc is a life science company engaged in discovery, development, and commercialization of new fertility treatments. Its patented technology is based on egg precursor cells found in the outer layer of a woman’s own ovaries.